Following the official approval of “recanemab,” a brand new drug that straight targets the causative agent of Alzheimer’s illness, the Chuikyo-Central Social Insurance Medical Council will start discussions on pricing and protection of public medical insurance beginning on the twenty seventh. begins.
The focus is on the right way to consider the effectiveness of medication and their impression on insurance coverage funds.